T-DM1 Approval Expanded for HER2-Positive Breast Cancer - Cancer Currents Blog National Cancer Institute sent this bulletin at 05/24/2019 10:34 AM EDT Having trouble viewing this email? View it as a Web page. You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below. T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast Cancer 05/23/2019 FDA has expanded the approved use of the drug ado-trastuzumab emtansine (Kadcyla), also called T-DM1, to include adjuvant treatment in some women with early-stage HER2-positive breast cancer.
